Early studies involving high dose atropine suggested that high dose atropine (0.5–1.0%) had a strong effect in slowing childhood myopia (1-5). It was not till the Atropine Treatment for Myopia (ATOM2) study that the potential of low doses atropine (LDA) was raised (6). Since then, there have been several RCTs involving LDA have been completed, and results published (7-27). These studies often include treatment of 1–2 years, some with a follow-up washout period (where treatment was stopped) or altered (3-4,7-11,14-17,24-27). These are set in different countries, with different racial compositions using different doses and formulations in children of different ages and baseline myopia (Table 1). Change can be measured over 1, 2 or 3 years; or as a change with a year (e.g., 2nd or 3rd year). Placebo results are shown in italic. *, significance from placebo. A, atropine; AL, axial length; APPLE, Atropine for the Prevention of Progression of Low myopia in Elert Children; ATOM, Atropine Treatment of Myopia; ATOM-J, Atropine Treatment of Myopia-Japan; AU, Australia; CHAMP, Childhood Atropine for Myopia Progression; CN, China; cyclo, cyclopentolate; EU, Europe; HK, Hong Kong; IN, India; JP, Japan; LAMP, low-concentration atropine for myopia progression; m, month; MOSAIC, Myopia Outcome Study of Atropine in Children; PEDIG, Pediatric Eye Disease Interest Group; SE, spherical equivalent; SG, Singapore; TW, Taiwan; US, United States; WA-ATOM, Western…
Published: June 30, 2026 6:50 am
Source: Annals of Translational Medicine — Read original